Boston Scientific plunges 16% after EP segment misses by $43M. Management defends 35% growth, says market expectations were too high. Champion trial data at ACC in March.

Boston Scientific Crashes 16% in Worst Day Since 1998 as EP Growth Fears Spook Investors

Boston Scientific acquires Penumbra for $14.5B at $374/share, a 19% premium. The deal adds thrombectomy leadership to BSX's cardiovascular portfolio.

Boston Scientific Pays $14.5 Billion for Penumbra, Betting Big on Thrombectomy

Q4 2025

Q3 2025

BOSTON SCIENTIFIC (BSX) Earnings Call Transcripts

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Q2 2024

Recent News about BOSTON SCIENTIFIC

Boston Scientific Crashes 16% in Worst Day Since 1998 as EP Growth Fears Spook Investors

Boston Scientific Pays $14.5 Billion for Penumbra, Betting Big on Thrombectomy